nach oben

Journal of Gastrointestinal Surgery

Erschienen in:

19.11.2019 | Review Article

Peritoneal Metastases in Colorectal Cancer: Biology and Barriers

verfasst von: Lai Xue, Neil H. Hyman, Kiran K. Turaga, Oliver S. Eng

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Advances in the molecular biology of tumor metastasis have paralleled the evolution in the management of metastatic disease from colorectal cancer. In this review, we summarize the current understanding of the mechanism of colorectal cancer metastases, in particular that of peritoneal metastases, as well as clinical data on the treatment of this disease.

Methods

A review of relevant English literature using MEDLINE/PubMed on the biology of colorectal cancer metastases, determinants of oligometastasis, and use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of metastatic colorectal cancer is presented.

Results

Recognition of oligometastasis in the evolution of colorectal peritoneal metastases provides the theoretical framework for which cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy is considered. Clearly, a subset of patients benefit from peritoneal metastasectomy.

Conclusion

Advances in cancer biology and clinical imaging promise to expand the role of cytoreductive surgery with or without intraperitoneal chemotherapy in the management of peritoneal metastases from colorectal cancer.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018; 9(1). https://doi.org/10.1038/s41467-018-04278-6.

Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of Clinical Oncology 2007; 25(29):4575–4580. https://doi.org/10.1200/JCO.2007.11.0833.CrossRefPubMed

Pfannschmidt J, Dienemann H, Hoffmann H. Surgical Resection of Pulmonary Metastases From Colorectal Cancer: A Systematic Review of Published Series. Annals of Thoracic Surgery 2007; 84(1):324–338.CrossRefPubMed

Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Journal of Clinical Oncology 2003; 21(20):3737–3743. https://doi.org/10.1200/JCO.2003.04.187.CrossRefPubMed

Verwaal VJ, Bruin S, Boot H, Van Slooten G, Van Tinteren H. 8-Year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Annals of Surgical Oncology 2008; 15(9):2426–2432. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, Facy O, Arvieux C, Lorimier G, Pezet D, Marchal F, Loi V, Meeus P, De Forges H, Stanbury T, Paineau J, Glehen O. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Journal of Clinical Oncology 2018; 36(18_suppl):LBA3503–LBA3503. https://doi.org/10.1200/jco.2018.36.18_suppl.lba3503.CrossRef

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331(6024):1559–1564.CrossRefPubMed

Jacobson R, Sherman SK, Dadaleh F, Turaga KK. Peritoneal Metastases in Colorectal Cancer. Annals of surgical oncology 2018; 25(8):2145–2151. https://doi.org/10.1245/s10434-018-6490-x.CrossRefPubMed

Hellman S, Weichselbaum RR. Oligometastases. Journal of Clinical Oncology 1995; 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8.CrossRefPubMed

10.

Weichselbaum RR, Hellman S. Oligometastases revisited. Nature Reviews Clinical Oncology 2011; 8(6):378–382.CrossRefPubMed

11.

Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts. Bmj 1984; 288(6419):749–751. https://doi.org/10.1136/bmj.288.6419.749.CrossRefPubMedPubMedCentral

12.

Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr H-A, Delaloye J-F, Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011; 481:85. https://doi.org/10.1038/nature10694 Accessed.

13.

Fidler IJ. Selection of successive tumour lines for metastasis. Nature New Biology 1973; 242(118):148–149. https://doi.org/10.1038/newbio242148a0.CrossRefPubMed

14.

Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 2009; 4(6). https://doi.org/10.1371/journal.pone.0005821.

15.

Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XH-F, Byrom D, Riera A, Rossell D, Mangues R, Massagué J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer cell 2012; 22(5):571–584. https://doi.org/10.1016/j.ccr.2012.08.013.CrossRefPubMedPubMedCentral

16.

Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature 2016; 529(7586):298–306. https://doi.org/10.1038/nature17038.CrossRefPubMedPubMedCentral

17.

Gupta GP, Massagué J. Cancer Metastasis: Building a Framework. Cell 2006; 127(4):679–695.CrossRefPubMed

18.

The deleted in colorectal cancer (DCC) gene: A candidate tumour suppressor gene encoding a cell surface protein with similarity to neural cell adhesion molecules. Cancer Surveys 1995; 24:3–17.

19.

Frewer KA, Sanders AJ, Owen S, Frewer NC, Hargest R, Jiang WG. A role for WISP2 in colorectal cancer cell invasion and motility. Cancer Genomics and Proteomics 2013; 10(4):187–196.PubMed

20.

Stein MK, Williard FW, Tsao M, Deschner B, Dickson PV, Glazer ES, Martin MG, Deneve JL. Molecular comparison of primary colorectal cancer (pCRC) with peritoneal metastases (PM). Journal of Clinical Oncology 2019; 37(4_suppl):498–498. https://doi.org/10.1200/jco.2019.37.4_suppl.498.CrossRef

21.

Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pagès F, Valge-Archer V, Galon J. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Science Translational Medicine 2016; 8(327). https://doi.org/10.1126/scitranslmed.aad6352.

22.

Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer and Metastasis Reviews 2003.

23.

Hugen N, Van de Velde CJH, De Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Annals of Oncology 2014; 25(3):651–657. https://doi.org/10.1093/annonc/mdt591.CrossRefPubMedPubMedCentral

24.

Gendler SJ. MUC1, The renaissance molecule. Journal of Mammary Gland Biology and Neoplasia 2001.

25.

Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005. https://doi.org/10.1016/j.ccr.2005.01.008.

26.

Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters β-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003. https://doi.org/10.1038/sj.onc.1206291.

27.

Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Annals of Surgical Oncology 2007; 14(12):3460–3471. https://doi.org/10.1245/s10434-007-9557-7.CrossRefPubMed

28.

Lemoine L, Sugarbaker P, Van Der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World Journal of Gastroenterology 2016.

29.

Chiang AC, Massagué J. Molecular Basis of Metastasis. New England Journal of Medicine 2008; 359(26):2814–2823. https://doi.org/10.1056/nejmra0805239.CrossRefPubMed

30.

Naxerova K, Reiter JG, Brachtel E, Lennerz JK, Van De Wetering M, Rowan A, Cai T, Clevers H, Swanton C, Nowak MA, Elledge SJ, Jain RK. Origins of lymphatic and distant metastases in human colorectal cancer. Science 2017; 357(6346). https://doi.org/10.1126/science.aai8515.

31.

Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Annals of Surgical Oncology 2009; 16(2):327–333. https://doi.org/10.1245/s10434-008-0234-2.CrossRefPubMed

32.

Dresen RC, De Vuysere S, De Keyzer F, Van Cutsem E, Prenen H, Vanslembrouck R, De Hertogh G, Wolthuis A, D’Hoore A, Vandecaveye V. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases. Cancer Imaging 2019; 19(1). https://doi.org/10.1186/s40644-018-0187-z.

33.

Tseng J, Bryan DS, Poli E, Sharma M, Polite BN, Turaga KK. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. The Lancet Oncology 2017; 18(6):711–712. https://doi.org/10.1016/S1470-2045(17)30336-4.CrossRefPubMed

34.

Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. Journal of Clinical Oncology 2012; 30(3):263–267. https://doi.org/10.1200/JCO.2011.37.1039.CrossRefPubMed

35.

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: 1996:359–374.

36.

Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. Annals of Surgical Oncology 2016; 23(1):114–119. https://doi.org/10.1245/s10434-015-4627-8.CrossRefPubMed

37.

Sluiter NR, Vlek SL, Wijsmuller AR, Brandsma HT, de Vet HCW, van Grieken NCT, Kazemier G, Tuynman JB. Narrow-Band Imaging Improves Detection of Colorectal Peritoneal Metastases: A Clinical Study Comparing Advanced Imaging Techniques. Annals of Surgical Oncology 2019; 26(1):156–164. https://doi.org/10.1245/s10434-018-7005-5.CrossRefPubMed

38.

Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Canadian Journal of Surgery 1989; 32(3):164–170.

39.

Sugarbaker PH. Peritonectomy procedures. In: Peritoneal Carcinomatosis: A Multidisciplinary Approach; 2007:247–264.

40.

Fernández-Trigo V, Stuart OA, Stephens AD, Hoover LD, Sugarbaker PH. Surgically directed chemotherapy: Heated intraperitoneal lavage with mitomycin C. In: 2011:51–61.

41.

Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010; 116(16):3756–3762. https://doi.org/10.1002/cncr.25116.CrossRefPubMed

42.

Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Journal of Clinical Oncology 2009; 27(5):681–685. https://doi.org/10.1200/JCO.2008.19.7160.CrossRefPubMed

43.

Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, Maggiori L, Dumont F, Ducreux M, Elias D. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Annals of Surgery 2013; 257(6):1065–1071. https://doi.org/10.1097/SLA.0b013e31827e9289.CrossRefPubMed

44.

Cashin PH, Mahteme H, Spång N, Syk I, Frödin JE, Torkzad M, Glimelius B, Graf W. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. European Journal of Cancer 2016. https://doi.org/10.1016/j.ejca.2015.09.017.

45.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2013; 14(12):1208–1215. https://doi.org/10.1016/S1470-2045(13)70447-9.CrossRefPubMed

46.

Yoon W, Alame A, Berri R. Peritoneal Surface Disease Severity Score as a predictor of resectability in the treatment of peritoneal surface malignancies. American Journal of Surgery 2014; 207(3):403–407. https://doi.org/10.1016/j.amjsurg.2013.09.021.CrossRefPubMed

47.

Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, Quadros CA, Somashekhar SP, Ceelen W, Dubé P, Li Y, Verwaal VJ, Glehen O, Piso P, Spiliotis J, Teo MCC, González-Moreno S, Cashin PH, Lehmann K, Deraco M, Moran B, de Hingh IHJT. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). European Journal of Surgical Oncology 2018; 44(12):1942–1948. https://doi.org/10.1016/j.ejso.2018.07.003.CrossRefPubMed

48.

Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Annals of Surgical Oncology 2014; 21(5):1501–1505. https://doi.org/10.1245/s10434-013-3061-z.CrossRefPubMed

49.

Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S. Cytoreductive surgery of colorectal peritoneal metastases: Outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS ONE 2015. https://doi.org/10.1371/journal.pone.0122816.

50.

Goere D, Glehen O, Quenet F, Ducreux M, Guilloit J-M, Texier M, Benhamou E, Elias D. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394). Journal of Clinical Oncology 2018; 36(15_suppl):3531. https://doi.org/10.1200/jco.2018.36.15_suppl.3531.CrossRef

51.

Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers A, Bemelman WA, Brandt A, Bremers A, Burger JWA, van Grevenstein WMU, Hemmer PHJ, de Hingh IHJT, Kok N, Tuynman J, Wiezer MJ, de Wilt JHW, Dijkgraaf MG, Tanis PJ. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial. Journal of Clinical Oncology 2019; 37(4_suppl):482. https://doi.org/10.1200/jco.2019.37.4_suppl.482.CrossRef

52.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, De La Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine 2015. https://doi.org/10.1056/NEJMoa1500596.

53.

Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg M V., Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet Oncology 2017. https://doi.org/10.1016/S1470-2045(17)30422-9.

54.

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D’Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017. https://doi.org/10.1038/nature22079.

55.

Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. British Journal of Cancer 2016. https://doi.org/10.1038/bjc.2016.161.

56.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011. https://doi.org/10.1002/cncr.26086.

57.

Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. British Journal of Surgery 2017.

58.

Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Disease 2016. https://doi.org/10.1111/codi.13130.

59.

Williamson SK, Johnson GA, Maulhardt HA, Moore KM, McMeekin DS, Schulz TK, Reed GA, Roby KF, MacKay CB, Smith HJ, Weir SJ, Wick JA, Markman M, Dizerega GS, Baltezor MJ, Espinosa J, Decedue CJ. A phase i study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer Chemotherapy and Pharmacology 2015. https://doi.org/10.1007/s00280-015-2737-4.

60.

Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Annals of Surgical Oncology 2008. https://doi.org/10.1245/s10434-007-9718-8.

Titel: Peritoneal Metastases in Colorectal Cancer: Biology and Barriers
verfasst von: Lai Xue
Neil H. Hyman
Kiran K. Turaga
Oliver S. Eng
Publikationsdatum: 19.11.2019
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Surgery / Ausgabe 3/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-019-04441-4

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Peritoneal Metastases in Colorectal Cancer: Biology and Barriers

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Darf man die Behandlung eines Neonazis ablehnen?

Deutlich weniger Infektionen: Wundprotektoren schützen!

Chirurginnen und Chirurgen sind stark suizidgefährdet

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Prognostic Impact of Lymph Node Excision in T1 and T2 Gallbladder Cancer: a Population-Based and Propensity Score-Matched SEER Analysis

How I Do It: Robotic Duodenal Sleeve Resection for Non-ampullary Benign Duodenal Neoplasms

Post-Operative Complications and Readmissions Associated with Smoking Following Bariatric Surgery

Clinical Outcomes of Minimally Invasive Enucleation of Leiomyoma of the Esophagus and Esophagogastric Junction

Lymph Node Noncompliance Affects the Long-Term Prognosis of Patients with Gastric Cancer after Laparoscopic Total Gastrectomy

Risk of Chronic Opioid Use in Opioid-Naïve and Non-Naïve Patients after Ambulatory Surgery

Update Chirurgie